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The aim of this study was to describe the incidence, clinical and histological characteristics, treatment and long-term follow-up of
bilateral germ-cell tumours (BGCT) of the testis in order to determine in what respects they differ significantly from unilateral germ-
cell tumours. In all, 31 patients with BGCT had metachronous tumours and 14 had synchronous tumours. Among the metachronous
tumours, 61% occurred more than 5 years after the first tumour. The overall incidence of BGCT in patients with testicular germ-cell
tumours (TGCT) was 1.9%. The incidence was 3.2% in patients presenting with a seminoma and 1.4 % in patients presenting with a
nonseminomatous germ-cell tumour (NSGCT). Patients under 30 years of age at the time of the initial diagnosis had a higher
incidence of bilateral tumours compared with older men. The outcome of BGCT was excellent. A high association was found
between BGCT, sterility and suspected genetic risk factors for TGCT. These results argue against a systematic contralateral biopsy at
diagnosis of first TGCT in all patients, but emphasise the importance of patient education and of the need to better identify patients
at risk for a second TGCT. Therapeutic indications for synchronous BGCT, including conservative treatment, need to be better
defined.
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Testicular germ-cell tumour (TGCT) is a rare disease with an
estimated incidence of five out of 100000. An increase of more
than 50% has been demonstrated in all Western countries during
the last decades (Grenlee et al, 2001). Several risk factors for
developing a TGCT have been identified, uppermost among which
is a previous TGCT (Osterlind et al, 1991). The incidence of
bilateral testicular germ-cell tumour (BGCT) ranges between 1 and
5% in previously published large series (Bokemeyer et al, 1993;
Dieckmann et al, 1993, 1999, 2002; Heidenreich et al, 1995, 1997,
2000; Gerl et al, 1997; Tekin et al, 2000; Geczi et al, 2001; Ondrus
et al, 2001; Che et al, 2002; Ohyama et al, 2002). The charts of 2383
consecutive patients treated at the Institut Gustave Roussy over a
22-year period were analysed to estimate the incidence of BGCT, to
identify potential risk factors and to evaluate the long-term
survival of patients with BGCT.
PATIENTS AND METHODS
Between 1979 and 2002, 2383 patients with TGCT were treated in
the Adult Cancer Department at the Institut Gustave Roussy (IGR).
The list of patients was obtained from a computerised database.
Among these 2383 patients, 45 had a BGCT. The medical records of
these 45 patients were reviewed to collect the following informa-
tion: previous personal and family medical history, clinical
characteristics at presentation, histopathology, treatment, interval
between the development of the two tumours and follow-up.
All available pathology slides were reviewed. Most patients had
their orchidectomy at other institutions. Haematoxylin- and eosin-
stained slides of both testicular tumours were available for 36
patients, and slides of only one tumour were available for three
patients. A pathology report was available in all cases.
All tumours were staged according to the TNM and the ICCCG
staging systems, which take into account the extent of the primary
tumour, retroperitoneal lymph nodes, distant metastases and
serum markers.
All patients were divided into two groups based on the
histological subtype of their testicular tumour: the seminoma
group comprised only patients with pure seminoma, and the
NSGCT group comprised patients with any mixture of germ-cell
tumour as long as one of the components was nonseminomatous
and any pure form of germ-cell tumour other than seminoma.
Patients were then divided into three groups according to their
age: 15–30, 30–45 and over 45 years. Patients’ treatment was
based on the histologic type and clinical stage.
All patients treated before 2001 had a bilateral orchidectomy.
Most patients with seminoma confined to the testis or with small
involved retroperitoneal lymph nodes had radiation therapy after
the orchidectomy, whereas most patients with either advanced
seminoma (with large retroperitoneal masses and/or distant
metastases) and most patients with NSGCT had chemotherapy
after orchidectomy. Whereas patients with NSGCT treated before
1985 had a systematic retroperitoneal lymph-node dissection
(RPND), this surgical procedure was restricted to patients with
residual masses after chemotherapy after 1985. Data were analysed
using the w
2 test ; P-values of less than 0.05 were considered to be
statistically significant.
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In all, 31 of the 45 patients had metachronous tumours
and 14 patients had synchronous tumours. The median age was
26 (range 16–58). Nine patients had a history of cryptorchidism
that was bilateral in five, three had a family history of TGCT,
one had a family history of bilateral testicular cryptorchidism,
seven had atypical nevi, one had Down’s syndrome,
one had piebaldism and one had a subsequent anal
squamous cell cancer. In total, 10 were explored for infertility
before the diagnosis of the germ-cell tumour, five of
whom had a metachronous BGCT and five a synchronous
BGCT.
Pathological features of BGCT
Seminoma was the predominant histology: among the 90 tumours,
54 were seminomas in 36 patients and 36 were NSGCT in 22
patients. Histology was concordant in 27 patients and discordant
in 18 patients.
In the 14 patients with synchronous tumours, histology was
concordant in 10 cases (nine with seminomas and one with
NSGCT) and discordant in four patients.
In the 31 men with metachronous tumours, histology
was concordant in 13 cases and discordant in 18: the tumour
was a seminoma in 32 testicles and NSGCT in 30 testicles.
In total, 14 patients presented with seminoma, nine of
whom developed a second seminoma, whereas five had an
NSGCT as their second tumour. In all, 17 patients presented
with NSGCT, eight of whom had a second NSGCT, whereas
nine developed seminoma as their second tumour. There
was no correlation in terms of histologic type between
the first and the second tumour in men with metachronous
tumours.
Incidence
Of the 2383 patients who were treated at the Institut Gustave
Roussy between 1979 and 2002, 45 patients (1.9%) developed a
BGCT of the testis.
The incidence of metachronous BGCT was 1.3% and that of
synchronous BGCT 0.6%.
The probability of developing a metachronous TGCT was
1.8% (0.9–2.8%. CI 95%) in patients who presented with
seminoma and 1.1% (0.6–1.8%. CI 95%) in patients who
presented with NSGCT, and this difference was not statistically
significant (P¼0.24) (Table 1). However, the incidence of
metachronous TGCT in patients with seminoma was markedly
influenced by the patient’s age at the time of presentation.
The probability of developing a metachronous BGCT was 3.9%
(1.8–7.2%. CI 95%) in patients who presented with seminoma
under the age of 30 years and 0.8% (0.3–1.9% CI 95%) in patients
older than 30 years who presented with seminoma and this
difference was statistically significant (Pp0.01). (Table 2). The
incidence of metachronous BGCT was also influenced by age in
patients with NSGCT with a probability of developing a
metachronous TGCT of 1.5% (0.8–2.5% CI 95%) in the p30
years age group and 0.5% (0.1–1.5%. CI 95%) in the X30 age
group. However, this difference was not statistically significant
(P¼0.08) (Table 3).
In the whole population with synchronous and metachronous
BGCT, 36 patients had at least one seminoma (out of 836 patients
treated for seminoma), 17 of whom were p30 when the seminoma
was diagnosed (out of 232 patients treated for seminoma p30).
The general incidence of BGCT in the seminoma patient
population was 4.3% (3–5.9%. CI 95%) and 7.3% (4.3–11.5%. CI
95%) in patients with seminoma p30.
Intervals between the first and the second tumour
In 31 patients with metachronous BGCT, the median interval
between the first and the second tumour was 60 months (range 4–
240). The second tumour occurred within 5 years in 13 patients
(41%) and between 10 and 20 years in seven patients
(23%).(Figure 1). It is noteworthy that nine patients had received
Cisplatin-based chemotherapy (VAB 6 in five patients, BEP in two,
EP in one and CISCA in one) during treatment of their first TGCT.
The median interval between the first and the second tumour
was 70 months (range: 43–154) in these patients.
Clinical features, treatment and outcome
Among the 31 patients with metachronous BGCT, the first tumour
was TNM stage I in 23 patients, stage II in seven patients, one
IGCCCG intermediate-risk BGCT and one IGCCCG good-risk stage
III BGCT. The treatment was radiotherapy in 14 patients,
retroperiteal lymph-node dissection (RPLND) alone in three
patients, surveillance after orchiectomy in five patients and
chemotherapy, possibly followed by RPLND, in nine patients.
The second tumour was stage I in 25 patients, stage II in three
Table 1 Histology-specific incidence of metachronous BGCT
Histology All patients Patients with BGCT %
Seminoma 836 14 1.8
NSGCT 1547 17 1.1
Table 2 Age-specific incidence of metachronous BGCT in patients
presenting with seminoma
Age group All patients with seminoma Patients Nb BGCT %
15–30 232 9 3.9
430 604 5 1.3
Total 836 14 1.7
Table 3 Age-specific incidence of metachronous BGCT in patients with
NSGCT
Age group All patients with NSGCT Patients Nb BGCT %
30–45 946 14 1.5
430 601 3 0.5
Total 1547 17 1
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Figure 1 Time intervals between first and second tumours in the 31
patients with metachronous bilateral testicular germ-cell tumours.
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one patient. The treatment was radiotherapy in six patients,
RPLND alone in two patients, surveillance after orchiectomy in 10
patients and chemotherapy in 13 patients.
Among the 14 synchronous BGCT, there was one stage I and four
stage II tumours, two of which were bilateral seminomas. One patient
had an IGCCCG intermediate-risk NSGCT. The treatment was
chemotherapy in seven patients and radiotherapy in seven patients.
The median follow-up was 58 months after the second tumour
or the BGCT (range 10–218). There was no substantial difference
in the TNM stage distribution between patients with seminoma
and patients with NSGCT. All 10 patients diagnosed with BGCT
after exploration of infertility had limited stage disease (nine
patients with stage I and one patient with stage II seminoma).
The overall prognosis of patients with BGCT was excellent as in
previous series in the literature (Coogan, Albers). One of the 45
patients with metachronous BGCT presented with poor prognosis
disease according to the IGCCCG staging system and ultimately
died of refractory metastatic disease. None of the remaining
patients had any evidence of disease at the most recent follow-up.
Five patients underwent conservative surgery: conservative surgery
was restricted to one testis in four patients but performed on both
testicles in one patient. One patient had metachronous discordant
BGCT with pure mature teratoma in the first tumour at 16 and
mixed TGCT with mature teratoma and seminoma, 67 months
later in the contralateral testis. The four other patients had
bilateral synchronous BGCT, which was bilateral seminoma in
three and discordant NSGCT and seminoma in the fourth patient.
Adjuvant treatment was chemotherapy with two cycles of BEP in
the two patients with NSGCT, chemotherapy with Carboplatin in
one patient with seminoma and radiotherapy at a dose of 20Gy to
the ipsilateral lymph nodes and the remaining testicular tissue in
two patients including the one patient who had bilateral
conservative surgery. All five patients have had regular follow-up
consultations with a three-monthly ultrasound and tumour marker
determination, and have no evidence of progression in the testis at
a median follow-up of 18 months. None of them require
substitutive hormone therapy.
DISCUSSION
It is well known that having a TGCT is the major risk factor for
developing a second TGCT in the contralateral testis with the
second tumour occurring in 1–5% of patients (Bokemeyer et al,
1993; Dieckmann et al, 1993, 1999 2002; Heidenreich et al, 1995,
1997, 2000; Gerl et al, 1997; Tekin et al, 2000; Geczi et al, 2001;
Ondrus et al, 2001; Che et al, 2002; Ohyama et al, 2002). The first
published series by Gilbert and Hamilton (1942) included 1466
consecutive patients and found an incidence of 1.6%. A review of
the literature spanning a period of 20 years, published by Aristibal
in 1986 found an incidence of 1.56% in 4864 patients. More
recently, Bokemeyer found an incidence of 3.5% in 773 patients
treated at Hanover University between 1972 and 1985 and
Kristiansund reported an incidence of 1.9% in 1300 consecutive
patients treated in Norway. Osterlind et al (1991); Bokemeyer et al
(1993); Dieckmann et al (1996, 1999, 2002); Gerl et al (1997), Geczi
et al (2001), Che et al (2002), respectively, found incidence rates of
2.6% in 2830 patients treated in Denmark between 1960 and 1979,
5% in 181 consecutive patients treated in Berlin, 2% in 787 patients
treated between 1979 and 1996 at the University of Munich, 3.5%
in 773 patients treated at the University of Hanover, 3% in 2386
consecutive patients treated in Hungary and 1% in 2431 patients
treated at the MD Anderson Cancer Centre over a period of 20
years. In all these series, the incidence of synchronous BGCT was
lower than that of metachronous BGCT of the testis. Dieckman
estimated an incidence of 0.1% in 89 published cases. Che found
three in a series of 24 patients with BGCT with an incidence of
0.4%, which is identical to that reported by Bokemeyer. In the large
series published by Geczi, the incidence was 0.8%. In our study
population of 2383 patients, 14 (0.6%) presented with synchronous
BGCT corresponding to an incidence of 0.6% and 31 patients
developed metachronous BGCT corresponding to an incidence of
1.3%, in the lower range of the published series (Patel et al, 1990,
1993; Park et al, 1999; Che et al, 2002). The incidence of BGCT may
increase in the future due to the development of infertility
exploration. Our study supports this premise because 10 of our
patients had been explored for infertility. Another reason why the
incidence of BGCT may increase could be the long-term survival of
patients diagnosed early and who received effective treatment for
their first tumour. Our study also supports this premise since
seven of the 31 patients with metachronous BGCT developed the
second tumour more than 10 years after the first tumour.
The incidence of BGCT has been reported to be different in
patients who have seminoma compared with patients who have
NSGCT. Osterlind reported a greater incidence in patients who had
NSGCT (8.4%) compared with patients who had seminoma (3.6%).
The reverse finding was observed by Bokemeyer, who found that
4.8% of patients who had seminoma developed BGCT compared
with 1.8% of those with NSGCT and by Che who found that 1.8% of
patients with seminoma compared with 0.6% of patients with
NSGCT developed BGCT and by Kristianslund. In the present
study, there were significantly more BGCT in seminoma patients
than in NSGCT patients. However, patients who initially presented
with a unilateral seminoma did not have a significantly higher risk
of developing a metachronous contralateral TGCT compared to
patients who presented with a unilateral NSGCT. The significance
of the seminoma histology in the population of patients with BGCT
remains unclear.
We also found that the incidence of BGCT in patients with
seminoma was influenced by the patient’s age at the time of the
initial diagnosis. Although seminoma was more common in
patients older than 30 years, the incidence of BGCT was much
greater in patients in the younger age group. Patients who had an
early-onset unilateral seminoma were at greater risk of developing
a contralateral TGCT. These results are similar to those published
by Che. Dieckman also found that patients with BGCT were
younger compared to men with a unilateral tumour, but did not
group patients according to histologic subtype. In the present
study, the increased incidence of BGCT in younger patients with
NSGCT was not statistically significant.
The association of BGCT and suspected risk factors for
developing a TGCT has not been systematically reported in most
series. Cryptorchidism is the best-known risk factor. Geczi
reported the association of BGCT and cryptorchidism in 9.5% of
cases, whereas no cases of cryptorchidism were reported in the MD
Anderson series (Che et al, 2002). Likewise, other conditions
reported to be associated with the risk of TGCT such as infertility
(Hendenreich), atypical nevi (Raghavan et al, 1994; Avril et al,
2001) or chromosomal abnormalities such as Down’s syndrome
(Roberge et al, 2001) are not reported in BGCT series. As all these
series are retrospective, it is possible that all background data were
not recorded in all patient files. The high association with such risk
factors demonstrated in this report are suggestive of a genetic
predisposition and supports the hypothesis that there may be
familial forms of BGCT, like in familial clustering of TGCT
(Skotheim, Rapley, Dong et al, 2001; Krazggerud et al, 2002).
The strategies employed for the management of TGCT were
based on the individual patient. (Tables 1 and 2). Treatment
decisions for patients with synchronous and metachronous BGCT
were based on risk stratification, as defined by the International
Germ Cell Cancer Collaborative Group International Germ Cell
Cancer Consensus Classification (1997). In patients with meta-
chronous BGCT, only three initially had surveillance for their first
NSGCT. One patient relapsed and was treated with chemotherapy.
Since nine of the 31 patients received three to six cycles of
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these results show that chemotherapy does not fully protect an
individual patient from the development of a second TGCT, unlike
that previously speculated (Bokemeyer et al, 1993; Park et al,
1999). Post-treatment surveillance of these patients consisted in
serum tumour marker determinations and imaging studies. The
time frame for surveillance was usually defined according to
disease presentation. The most common timing of follow-up was
evaluation every 3 months for 2 years, every 6 months for the next
3 years and yearly thereafter.
Most of the second tumours were detected during follow-up.
However, in some of the patients, the second tumour was detected
through self-examination and, in one patient through a metastasis
while he had interrupted follow-up. There was no decrease in the
incidence of a second TCGT with time and the longest interval
between tumours was 20 years. Intervals as long as 32 years
between tumours were reported in one series (Schreiber et al,
1987). Consequently, patients with TGCT require life-long follow-
up with periodic self-examination and ultrasonography, which is a
sensitive and reliable detection method (Patel et al, 1990, 1993).
The treatment decisions for the second tumour were determined
mainly according to the clinical and pathological characteristics of
the second tumour and, sometimes, according to the treatment of
the first tumour. Only two patients had a repeated retroperitoneal
lymph-node dissection. In all, 11 patients were offered surveillance
for low-risk stage I seminoma or NSGCT. One of them relapsed
and was rendered disease free with chemotherapy.
Five patients treated after 2001 underwent conservative surgery.
The adjuvant treatments were different and were according
to pathological findings and at the physician’s discretion.
Testis-preserving surgery is more and more widely used
for patients with BGCT (Heidenreich et al, 1995, 1997, 2000;
Mearini et al, 1996; Fernandez Aparicio et al, 2000; Kirkali et al,
2001). A 20 Gy irradiation dose to the remaining testis has been
reported to be a safe approach (Petersen et al, 2002). However,
local relapses have also been reported following this treatment
modality (Dieckmann et al, 1993, 1999, 2002). Neoadjuvant or
adjuvant chemotherapy have been used to permit conservative
treatment. (Oliver et al, 1996; Sawyer et al, 1999). Testicular
relapses were observed in that series of patients, but had no impact
on survival. Apparently, none of the conservative strategies are
totally safe, but organ-sparing surgery in patients with BGCT offers
endocrinological and psychological advantages. It should only be
offered to patients who are aware and accept the risk of a
subsequent local relapse and who realise the importance of
compliance during follow-up.
Testicular intratubular germ-cell neoplasia is considered a
precursor lesion for developing germ-cell tumours. It has been
reported that at least 5% of patients with testicular germ-cell
tumour have intratubular germ-cell neoplasia in the contralateral
biopsy specimen when they undergo orchidectomy (Dieckmann
et al, 1993, 1999, 2002; Daugaard et al, 1996; Herr and Scheifeld,
1997). Consequently, it has been suggested that patients with
unilateral germ-cell tumours should undergo a systematic
contralateral testicular biopsy at the time of orchidectomy to
evaluate intratubular germ-cell neoplasia and identify patients who
may develop a second germ-cell tumour (Dieckmann et al, 1993,
1999, 2002; Daugaard et al, 1996; Harland et al, 1998). However,
the 1.3% incidence rate that we found for metachronous BGCT is
significantly different compared with the reported incidence of
intratubular germ-cell neoplasia if systematic contralateral biop-
sies are performed. This suggests that intratubular germ-cell
neoplasia occurs more frequently than invasive germ-cell tumours.
It has been reported that about 50% of patients with intratubular
germ-cell neoplasia who do not receive radiation therapy to the
testis nor systemic chemotherapy will develop an invasive germ-
cell tumour at 5 years (Montinori, 2002). Since a contralateral
biopsy has no adverse effect in itself, it could be recommended as a
routine procedure. However, this procedure may lead to a false
sense of safety since false-negative biopsy results have been
reported (Dieckmann et al, 1993, 1999, 2002). The same
surveillance would therefore have to be recommended for patients
with negative biopsy results. Furthermore, there is no consensus
about the management of patients with intratubular neoplasia.
Whether all patients with germ-cell intratubular neoplasia should
receive radiotherapy to the contralateral testis remains debatable.
The extent of radiotherapy in this indication is also controversial,
(Classen et al, 2000; Sedlmayer et al, 2001; Petersen et al, 2002).
Delivering doses below 20 Gy is not considered safe and local
relapses have been reported even at this dose (Dieckmann et al,
1993, 1999, 2002). Although the fertility of patients with
intraepithelial germ-cell neoplasia is generally poor, it has been
reported to be sufficient in some patients to father a child
(Bokemeyer et al, 1993; Jacobsen et al, 2002), while radiotherapy to
the contralateral testis results in definitive infertility. Radiotherapy
may also affect Leydig cell function, even at the lowest doses (Von
der Maase et al, 1986; Dieckman et al, 1993, 1999, 2002; Petersen
et al, 2002).
Close clinical follow-up may therefore be recommended for
patients with a unilateral germ-cell tumour and characteristics
such as microlithiasis at ultrasonography (Berger and Brabrand,
1998) or testicular atrophy or impaired gonadal function (Harland
et al, 1998), which lead to suspicion of contralateral intraepithelial
neoplasia, since there is concern about the effect of radiotherapy.
Chemotherapy has also been reported to lower the incidence of
metachronous BGCT, with an estimated risk of recurrent
intraepithelial germ-cell neoplasia of 21 and 42% at 5 and 10
years, respectively (Oliver et al, 1996). This finding associated with
the long-term experience with single-agent carboplatin for clinical
stage I seminoma (Steiner et al, 2002) may lead to recommenda-
tions for treatment with this cytotoxic agent rather than radio-
therapy for patients presenting with seminoma below 30 years of
age.
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